Introduction: The Paradox of Remission in Crohn’s Disease
For decades, the primary goal of treating Crohn’s disease (CD) has been the induction and maintenance of clinical remission—a state characterized by the absence of symptoms and, more recently, endoscopic evidence of mucosal healing. However, even when patients achieve what appears to be stable remission through advanced biologics and immunosuppressants, the risk of relapse remains high. This clinical reality suggests that the underlying pathophysiology of the disease is not fully resolved by immune suppression alone. A landmark study by Braun et al., published in Gastroenterology, provides a multi-omic deep dive into why this happens, revealing that despite effective suppression of the adaptive immune system, significant perturbations in diet, gut microbiota, and epithelial health persist.
